Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 109, Issue 9, Pages 3528-3533Publisher
NATL ACAD SCIENCES
DOI: 10.1073/pnas.1114502109
Keywords
-
Categories
Funding
- Huntington Society of Canada
- Canadian Institutes for Medical Research [MOP-172515, MOP-111219, MOP-165174]
- Canada Foundation for Innovation
- Alberta Innovates-Health Solutions (AIHS)
Ask authors/readers for more resources
Huntington disease (HD) is a progressive neurodegenerative monogenic disorder caused by expansion of a polyglutamine stretch in the huntingtin (Htt) protein. Mutant huntingtin triggers neural dysfunction and death, mainly in the corpus striatum and cerebral cortex, resulting in pathognomonic motor symptoms, as well as cognitive and psychiatric decline. Currently, there is no effective treatment for HD. We report that intraventricular infusion of ganglioside GM1 induces phosphorylation of mutant huntingtin at specific serine amino acid residues that attenuate huntingtin toxicity, and restores normal motor function in already symptomatic HD mice. Thus, our studies have identified a potential therapy for HD that targets a post-translational modification of mutant huntingtin with critical effects on disease pathogenesis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available